Lorenzo Tallarigo Net Worth

The estimated Net Worth of Lorenzo Tallarigo is at least $193 Million dollars as of 7 July 2014. Lorenzo Tallarigo owns over 2,000 units of Lilly(Eli) & Co stock worth over $1,841,780 and over the last 19 years Lorenzo sold LLY stock worth over $191,260,763.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Lorenzo Tallarigo LLY stock SEC Form 4 insiders trading

Lorenzo has made over 15 trades of the Lilly(Eli) & Co stock since 2005, according to the Form 4 filled with the SEC. Most recently Lorenzo exercised 2,000 units of LLY stock worth $19,640 on 7 July 2014.

The largest trade Lorenzo's ever made was selling 1,123,415 units of Lilly(Eli) & Co stock on 15 October 2013 worth over $70,213,438. On average, Lorenzo trades about 49,906 units every 102 days since 2005. As of 7 July 2014 Lorenzo still owns at least 2,000 units of Lilly(Eli) & Co stock.

You can see the complete history of Lorenzo Tallarigo stock trades at the bottom of the page.

What's Lorenzo Tallarigo's mailing address?

Lorenzo's mailing address filed with the SEC is Eli Lilly and Company Corporate Center, Indianapolis, Marion County, Indiana, United States.

Insiders trading at Lilly(Eli) & Co

Over the last 20 years, insiders at Lilly(Eli) & Co have traded over $29,994,829,903 worth of Lilly(Eli) & Co stock and bought 73,808 units worth $5,778,435 . The most active insiders traders include Endowment Inc Lilly, R David Hoover, and Lorenzo Tallarigo. On average, Lilly(Eli) & Co executives and independent directors trade stock every 7 days with the average trade being worth of $55,447,708. The most recent stock trade was executed by Endowment Inc Lilly on 3 September 2024, trading 24,084 units of LLY stock currently worth $23,281,762.

What does Lilly(Eli) & Co do?

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.

Complete history of Lorenzo Tallarigo stock trades at Intercept Pharmaceuticals Inc and Lilly(Eli) & Co

Lilly(Eli) & Co executives and stock owners

Lilly(Eli) & Co executives and other stock owners filed with the SEC include:

• David Ricks,
  Chairman of the Board, President, Chief Executive Officer
• Joshua Smiley,
  Chief Financial Officer, Senior Vice President
• Daniel Skovronsky,
  Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories
• David A. Ricks,
  Chairman, CEO & Pres
• Anat Hakim J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Jackson Tai,
  Independent Director
• Juan Luciano,
  Lead Independent Director
• J. Erik Fyrwald,
  Independent Director
• Karen Walker,
  Independent Director
• William Kaelin,
  Independent Director
• Michael Eskew,
  Independent Director
• Jamere Jackson,
  Independent Director
• Katherine Baicker,
  Independent Director
• Raul Alvarez,
  Independent Director
• Kathi Seifert,
  Independent Director
• Marschall Runge,
  Independent Director
• Carolyn Bertozzi,
  Independent Director
• Alfonso Zulueta,
  Senior Vice President, President - Lilly International
• Ilya Yuffa,
  Senior Vice President and President of Lilly Bio-Medicines
• Anne White,
  Senior Vice President, President - Lilly Oncology
• Leigh Pusey,
  Senior Vice President - Corporate Affairs and Communications
• Myles O'Neill,
  Senior Vice President and President - Manufacturing Operations
• Johna Norton,
  Senior Vice President - Global Quality
• Michael Mason,
  Senior Vice President and President, Lilly Diabetes
• Patrik Jonsson,
  Senior Vice President, President of Lilly USA , and Chief Customer Officer
• Stephen Fry,
  Senior Vice President - Human Resources and Diversity
• Anat Hakim,
  Senior Vice President, General Counsel
• Melissa Barnes,
  Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
• Aarti Shah,
  Senior Vice President - Chief Information and Digital Officer
• Leigh Ann Pusey,
  Sr. VP of Corp. Affairs & Communications
• Alonzo Weems,
  Sr. VP and Chief Ethics & Compliance Officer
• Diogo Rau,
  Sr. VP & Chief Information and Digital Officer
• Kevin Hern,
  VP of Investor Relations
• Martin Bott MIBS,
  VP of Fin. & Special Projects
• Donald A. Zakrowski,
  Chief Accounting Officer & VP of Fin.
• Jacob S. Van Naarden,
  Chief Operating Officer of Loxo Oncology
• Anat Ashkenazi,
  Sr. VP & CFO
• Eric Dozier,
  EVP, HR & Diversity
• Endowment Inc Lilly,
  
• Christi Shaw,
  SVP and Pres., Lilly Bio-Meds
• Fionnuala M Walsh,
  SVP, Global Quality
• Jan M Lundberg,
  EVP,Science&Tech and Pres. LRL
• Maria A Crowe,
  President, Mfg. Operations
• Ralph Alvarez,
  Director
• Michael J Harrington,
  Senior VP and General Counsel
• Jeffrey N Simmons,
  SVP&Pres.,Elanco Animal Health
• Susan Mahony,
  SVP, HR & Diversity
• Barton R Peterson,
  Sr. VP, Corp. Affairs & Comm.
• Derica W Rice,
  Sr. Vice President and CFO
• Enrique A Conterno,
  Sr. VP & Pres., Lilly Diabetes
• Naarden Jacob Van,
  EVP & Pres., Loxo@Lilly
• Donald A Zakrowski,
  SVP, Finance, & CAO
• Karen N Horn,
  Director
• John C Lechleiter,
  President and COO
• Alonzo Weems,
  EVP, ERM & CECO
• R David Hoover,
  Director
• Franklyn G Prendergast,
  Director
• Ellen R Marram,
  Director
• Douglas R Oberhelman,
  Director
• Anne Nobles,
  Chief Eth/Cmpl Ofcr & SVP, ERM
• Bryce D. Carmine,
  EVP and Pres, Lilly Bio-Meds
• Robert A Armitage,
  Sr. VP and General Counsel
• Steven M Paul,
  EVP, Science and Technology
• Frank M Deane,
  President, Manufacturing
• J Michael Cook,
  Director
• Alfred G Gilman,
  Director
• Martin S Feldstein,
  Director
• Sidney Taurel,
  Chairman, President and CEO
• Alex M Ii Azar,
  Sr. VP, Corp. Affairs & Comm.
• Gino Santini,
  Sr.VP, Corp. Strategy & Policy
• Deirdre P Connelly,
  President, Lilly USA
• Anthony John Murphy,
  Senior VP, Human Resources
• Jacques Tapiero,
  SVP&Pres., Emerging Markets
• Winfried F W Sir Bischoff,
  Director
• Arnold C Hanish,
  Chief Accounting Officer
• Lorenzo Tallarigo,
  President, Internat'l Opers.
• George M C Fisher,
  Director
• Scott A Canute,
  President, Mfg. Operations
• Charles E Golden,
  Exec. Vice President and CFO
• Kimberly H Johnson,
  Director
• Anat Ashkenazi,
  EVP & CFO
• Diogo Rau,
  EVP & CIDO
• Edgardo Hernandez,
  EVP & Pres., Mfg. Operations
• Gabrielle Sulzberger,
  Director
• Mary Lynne Hedley,
  Director
• Melissa Seymour,
  EVP, Global Quality